Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BIRK NYSEAMERICAN:EQX NASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIRKBirkenstock$41.41+0.1%$37.01$31.12▼$57.20$7.61B1.152.81 million shs4.47 million shsEQXEquinox Gold$12.13$14.02$5.61▼$18.96$9.57B1.219.42 million shs5.75 million shsIMCRImmunocore$28.83$30.07$27.56▼$40.71$1.46B0.74306,307 shs689,631 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIRKBirkenstock0.00%+32.73%+5.30%+6.66%-22.27%EQXEquinox Gold0.00%-8.31%-15.35%-32.04%+80.51%IMCRImmunocore0.00%+2.78%-1.60%-12.45%-7.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIRKBirkenstock$41.41+0.1%$37.01$31.12▼$57.20$7.61B1.152.81 million shs4.47 million shsEQXEquinox Gold$12.13$14.02$5.61▼$18.96$9.57B1.219.42 million shs5.75 million shsIMCRImmunocore$28.83$30.07$27.56▼$40.71$1.46B0.74306,307 shs689,631 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIRKBirkenstock0.00%+32.73%+5.30%+6.66%-22.27%EQXEquinox Gold0.00%-8.31%-15.35%-32.04%+80.51%IMCRImmunocore0.00%+2.78%-1.60%-12.45%-7.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIRKBirkenstock 2.71Moderate Buy$53.6829.63% UpsideEQXEquinox Gold 3.13Buy$17.0040.15% UpsideIMCRImmunocore 2.60Moderate Buy$57.75100.31% UpsideCurrent Analyst Ratings BreakdownLatest EQX, BIRK, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026BIRKBirkenstock The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.505/15/2026BIRKBirkenstock Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/14/2026BIRKBirkenstock Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$41.005/14/2026BIRKBirkenstock Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$41.005/14/2026BIRKBirkenstock BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $60.005/14/2026BIRKBirkenstock Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$60.00 ➝ $45.005/13/2026BIRKBirkenstock Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$51.005/7/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Strong-Buy4/27/2026BIRKBirkenstock Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$60.00 ➝ $55.004/27/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/22/2026BIRKBirkenstock Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $56.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIRKBirkenstock$2.18B3.49$2.70 per share15.31$18.41 per share2.25EQXEquinox Gold$1.82B5.27$0.70 per share17.41$7.76 per share1.56IMCRImmunocore$400.02M3.65N/AN/A$7.77 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIRKBirkenstock$385.46M$2.2118.7015.221.6616.26%12.95%7.15%8/13/2026 (Estimated)EQXEquinox Gold$221.47M$0.5415.168.85N/A21.72%10.26%5.77%8/12/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A262.09N/A-6.68%-7.07%-2.55%8/6/2026 (Estimated)Latest EQX, BIRK, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026EQXEquinox Gold$0.29$0.28-$0.01N/A$896.94 million$861.59 million5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBIRKBirkenstockN/AN/AN/AN/AN/AEQXEquinox Gold$0.060.49%N/A11.11%N/AIMCRImmunocoreN/AN/AN/AN/AN/ALatest EQX, BIRK, and IMCR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2026EQXEquinox Goldquarterly$0.01500.49%5/21/20265/21/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIRKBirkenstock0.452.951.19EQXEquinox Gold0.101.240.75IMCRImmunocore1.004.184.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIRKBirkenstock19.93%EQXEquinox Gold38.85%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipBIRKBirkenstockN/AEQXEquinox Gold8.35%IMCRImmunocore10.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIRKBirkenstock8,400183.91 millionN/AOptionableEQXEquinox Gold5,219789.08 million723.19 millionNot OptionableIMCRImmunocore32050.69 million45.58 millionOptionableEQX, BIRK, and IMCR HeadlinesRecent News About These CompaniesWall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a BetMay 22 at 10:56 AM | zacks.comImmunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 ShMay 14, 2026 | cnn.comHC Wainwright Brokers Lift Earnings Estimates for ImmunocoreMay 12, 2026 | marketbeat.comQ1 Earnings Forecast for Immunocore Issued By HC WainwrightMay 11, 2026 | marketbeat.comImmunocore (NASDAQ:IMCR) Upgraded by Zacks Research to "Strong-Buy" RatingMay 9, 2026 | marketbeat.comImmunocore (NASDAQ:IMCR) Raised to "Buy" at Wall Street ZenMay 9, 2026 | marketbeat.comA Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival DataMay 8, 2026 | finance.yahoo.comImmunocore (IMCR) Is Up 10.1% After Q1 Profitability Jumps On Higher Revenue And EfficiencyMay 7, 2026 | finance.yahoo.comImmunocore (NASDAQ:IMCR) Issues Earnings Results, Beats Expectations By $0.51 EPSMay 6, 2026 | marketbeat.comImmunocore reports first quarter financial results and provides a business updateMay 6, 2026 | globenewswire.comHussman Strategic Advisors Inc. Purchases Shares of 42,000 Immunocore Holdings PLC Sponsored ADR $IMCRMay 4, 2026 | marketbeat.comImmunocore (NASDAQ:IMCR) Rating Lowered to "Strong Sell" at Zacks ResearchApril 29, 2026 | marketbeat.comImmunocore (IMCR) to Release Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Hold" from AnalystsApril 25, 2026 | marketbeat.comKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaApril 19, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR)April 16, 2026 | theglobeandmail.comImmunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comA Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth ConcernsMarch 28, 2026 | finance.yahoo.comJefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price TargetMarch 25, 2026 | insidermonkey.comImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meetingMarch 17, 2026 | globenewswire.comJefferies downgrades Immunocore Holdings plc - depositary receipt (IMCR)March 17, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEQX, BIRK, and IMCR Company DescriptionsBirkenstock NYSE:BIRK$41.41 +0.03 (+0.07%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$41.44 +0.03 (+0.06%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Birkenstock Holding plc manufactures and sells footwear products. It also offers sandals, shoes, closed-toe silhouettes, skincare products, and accessories. The company sells its products through e-commerce sites and a network of owned retail stores, as well as business-to-business channels. It operates in the United States, Brazil, Canada, Mexico, Europe, APMA, and internationally. Birkenstock Holding plc was founded in 1774 and is based in London, the United Kingdom. Birkenstock Holding plc is a subsidiary of BK LC Lux MidCo S.à r.l.Equinox Gold NYSEAMERICAN:EQX$12.13 0.00 (0.00%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$12.20 +0.07 (+0.58%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equinox Gold Corp. engages in the exploration, acquisition, development, and operation of mineral properties in the Americas. It explores gold and silver deposits. It holds interest in properties in California located in the United States; Guerrero State located in Mexico; Maranhão, Bahia, and Mina Gerais state located in Brazil; and Ontario, Canada. The company was formerly known as Trek Mining Inc. and changed its name to Equinox Gold Corp. in December 2017. Equinox Gold Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.Immunocore NASDAQ:IMCR$28.83 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.92 +0.10 (+0.33%) As of 05/22/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
